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Slllmmary 
The fusogenic (F) domain of human lmmunodeficiency  virus (HIV) gp41 envelope (env) protein 
has sequence similarities to many viruses and mediates the fuston of HIV-infected cells. During 
a survey of the lmmunogenidty of HIV env peptldes in chimpanzees,  we have observed that 
HIV peptide immunogenicity was dramatically  altered by the NH2-terminal synthesis of the 
gp41 F domain to an otherwise immunogenic peptide.  We compared two hybrid peptlde types 
comprised ofT helper (Th) and B cell epitopes ofHIV gp120 env protein for their immunogenicity 
in chimpanzees. The Th-B epitope hybrid peptldes contained the HIV gp120 Th cell determinant, 
T1 (amino acids [aa] 428-440)  -synthesized  NH2 terminal to gp120 V3 loop peptides,  which 
contain B cell epitopes that induce anti-HIV-neutralizing antibodies (SP10IIIB [aa 303-321] and 
SP10IIIB [A] [aa 303-327]).  The F-Th-B peptide contained the HIV gp41 F domain of HIVIIIB 
gp41 (aa 519-530) -synthesized NH2 termmal to the Th-B peptide. Whereas Th-B peptldes were 
potent immunogens for chimpanzee antibody and T cell-proliferative responses, the F-Th-B peptide 
induced lower anti-HIV gp120 T and B cell responses. Moreover, lmmumzation of chimpanzees 
with F-Th-B peptide but not Th-B peptides induced a significant decrease m peripheral blood 
T lymphocytes (mean decrease during immunization, 52%; p <0.02). Chimpanzees previously 
immunized with F-Th-B peptide did not respond well to immunization with Th-B peptide with 
T or B cell responses to HIV peptides, demonstrating that the F-Th-B peptide induced immune 
hyporesponsiveness to Th and B HIV gp120 env determinants. These observations  raise the 
hypothesis  that the HIV gp41 env F domain may be a biologically  active immunoregulatory 
peptlde m wvo, and by an as yet uncharacterized mechamsm, promotes primate immune system 
hyporesponsiveness to otherwise immunogenic peptides. 
T 
o design immunogens that induced Th and B cell-neu- 
tralizing antibody responses against HIV, we have de- 
signed synthetic peptldes (Th-B) comprised of linear arrays 
of functional regions of the HIV envelope (env)  1 (1-3). The 
T1 sequence ofHIV gp120 (amino acids [aa]428-440) is part 
of a conformational determinant of the CD4 binding site (4), 
1 Abbrevtaaons used m thts paper, aa,  amino acids, E/C,  experimental/ 
control; env, envelope, F, fusogenic 
and is a potent Th epitope  (5). The gp120 SP10(A) region 
(aa 303-327)  contains  a potent B cell determinant (B) lo- 
cated in the V3 principle neutralizing domain of HIV gp120 
env (3,  6,  7),  and,  as  well, contains  a  CTL  epitope  for 
CD8 § cells that is restricted  m mice by H2D  a (8) and in 
humans by HLA-A2 (9). The HIV gp41 env fusogemc (F) 
domain (aa 519-530)  mediates fusion of HIV-infected cells 
(10, 11). We have previously observed that Th-B and F-Th-B 
peptides from HIVMN induced high-titered anti-HIV-neu- 
tralizing antibodies in goats (M. K. Hart and B. F. Haynes, 
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in  mice  against  H2D a  target  cells  expressing  native  HIV 
gp120  (2). 
While the role for the HIV gp41 F domain in mediation 
of cytopathic effects of HIV is estabhshed, an tmmunoregula- 
tory role for the F  domain has not been described.  In th~s 
study, we found that Th-B peptides were potent immunogens 
and  induced  high-meted  serum  antibody  and  PBMC- 
proliferative responses to ~mmunizmg pept~de and to gp120 
protein in chimpanzees. In contrast, the F-Th-B peptide that 
contained the HIV gp41 F domain did not reduce high levels 
of antipeptide or anti-gp120 T and B cell responses, but rather 
induced relative peripheral blood T lymphopema and ~mmune 
hyporesponsiveness to H1V gp120 env Th and B determinants. 
Materials and Methods 
Peptides  Peptides used m the study are hsted m Table 1  Pep- 
txde synthesis was performed using exther t-boc or f-moc chemistry 
with a peptide synthesxzer (A431; Apphed Blosystems, Inc., Foster 
Cxty, CA)  Peptides were purified using HPLC, and the molecular 
weight was determmed by fast atom bombardment mass spectrom- 
etry (R. B. Van Breeman, North Carohna State Umvers~ty,  Ra- 
leigh, NC) using a double-focusing mass spectrometer (HXIIOHF, 
Joel Ltd, Tokyo, Japan)  For Th-B and F-Th-B peptxdes (Table 1), 
expected molecular weight of F-Th-B peptide, F-T1-SP10IIIB(A), 
was 5,908, observed was 5,907; expected molecular weight of Th-B 
peptlde, T1-SP10IIIB, was 4,061, observed was 4,062,  expected and 
observed molecular weight of Th-B pepude, T1-SPl0IIIB(A), was 
4,749, and expected and observed molecular weight of Th-B pep- 
tide, T1-SP10MN(A), was 4,771  For the peptldes used m the study 
(Table 1) the pept~de arriounts are gross weights. The percent water 
by Karl F~sher test (Galbra~th Laboratories, Inc, Knoxwlle, TN) 
for each peptlde was F-T1-SPl0IIIB(A), 6%, T1-SPIOIIIB(A), 8%, 
T1-SP10IIIB, 6%,  and T1-SP10MN(A),  8%. 
Animals.  Chimpanzees were housed at t~he New Mexico State 
Universxty Primate Factlity (Alamorgordo, NM) and were studied 
usmg protocols approved by the U.S. Department of Health and 
Human Serwces and Natmnal Instxtutes of Health primate research 
comrmttees, and by the New Memco State Umverslty Ammal Utth- 
zat~on Commxttee  Chimpanzee nos. 884 (15 yr old) and 1028 (12 
yr old) had the same sire,  ammals 1045 (10 yr old) and 1070 (11 
yr old) were unrelated to each other and to ammals 884 and 1028 
Outbred goats were housed at the Duke Umverslty Ammal Facah- 
ties and studied using experimental protocols approved by the Duke 
Umverslty Ammal Use Committee  Ammal care and study proce- 
dures followed American Assoc~atlon of Laboratory Ammal Care 
gmdehnes 
Immumzat,ons  For goats, 3 mg of pepnde was rejected intra- 
muscularly m  each gluteal regmn m  CFA (first  dose),  and then 
IFA (subsequent doses). For anmumzatlon of chimpanzees,  var3ang 
doses of peptldes were rejected intramuscularly m  IFA m  a total 
volume of 4 cm 3,  with  1 cm  3 xnjected into right  and left upper 
arms and thighs 
ELISAs.  2/~g of Th-B peptlde,  T1-SP10IIIB,  or rgp120IIIB 
(Rephgen  Corp.,  Cambridge,  MD)  m  CBC  buffer  (15  mM 
NazCO3, 35 mM NaHCO3, pH 9.6) was incubated overmght m 
each well of a 96-well flat-bottomed plate (3590; Costar, Cambridge, 
MA)  Wells  were blocked with CBC buffer supplemented with 
3% BSA for at least 2 h and then washed three umes with PBS, 
0 05% Tween 20  Primary antibody at various concentrations m 
serum diluent (95 ml PBS, 0.05% Tween 20, supplemented with 
5 g BSA and 2 ml normal serum from same species as secondary 
antibody) was incubated for 90 mm at 20~  After washmg three 
times,  alkahne phosphatase-conjugated  secondary antibody was 
added to each well (60 mm at room temperature), and the plates 
were washed  Substrate (1 mg/mlp-mtrophenyl phosphate, Sigma 
Chemical Co, St. Lores,  MO) in 0 05 M  CBC, 0 002 M MgCI2 
was added to each well, and plates were developed (60 ram, 20~ 
m the dark and read at 405 nm on an ELISA reader (Anthros, Denley 
Instruments Co, Durham, NC). Endpomt ELISA antibody tlters 
were defined as the serum t~ter at which the experimental/control 
(E/C) OD value was >--3.0. 
HIV Neutrahzation Assays  The ablhty of chimpanzee or goat 
serum antibodies to neutrahze HIV was determined m syncytmm 
mhlbmon assay and reverse transcnptase mhlbmon assay as previ- 
ously described (1, 3)  Sera were heat macuvated (30 mm, 56~ 
before each assay. 
PBMC Isolation and In Vztro FH]Thymzdme Incorporation Assays. 
Chimpanzee or goat PBMC were isolated by standard density cen- 
tnfugatlon techniques (1, 12). In vatro assays of [3H]thymldme m- 
corporation were performed as described (1, 13)  For chimpanzee 
PBMC assays, m vitro cultures were performed usmg 10% normal 
chimpanzee serum  Antigens used m PBMC prohferatlon were the 
Table  1.  Sequences of Synthetic Pept,de Constructs Derived  from HIVMN and HIVIIIB env gp120 
Peptlde composition and  sequence (epltope type) 
Pepude  name  Peptlde type  F  TI(Th)  SP10  (B cell)  A(B cell) 
F-T1-SP10IIIB(A)  F-Th-B 
T1-SP10IIIB (A)  Th-B 
T1-SP10IIIB  Th-B 
T1-SP10MN  (A)  Th-B 
AVGIGALFLGFLKQIINMWQEVGKAMYACTRPNNNTRKSIILIQKGPGRAFVTI 
KQIINMWQEVGKAMYACTRPNNNTRKSIILIQKGPGRAFVTI 
KQIINMWQEVGKAMYACTRPN NNTRKSIKIQKGPG 
KQIINMWQEVGKAMYACTRPNYNKRKRIHIGPGRAFYTTK 
Each amino actd is represented by a single-letter code that is the first letter  of its name, except for argmme (R), asparagme (N),  glutamme (Q), 
glutamtc acid (E), lysme (K), phenylalamne (F), tryptophan (W), tyrosme (Y), and aspartlc acid (D)  F domain sequence is aa 519-530 from HIVIIIB 
(27)  T1 sequence is aa 428-443 from HIVIUB (27) SP10MN (A) sequence is aa 301-319 from HIVMN (28)  SP1011IB sequence is aa 303-321 
from HIVIIIB (A) sequence is aa 320-324 from HIVMN (28) and aa 322-327 from HIVIIIB (27) Th, Th cell determinant, B cell, B cell-neutrahzmg 
anttbody determinant  A, addmonal HIV gpl20 V3 loop sequences added to the original synthetic peptlde (SP10) sequence to add an addmonal 
neutrahzmg  and CTL regmn to the HIV B cell determinant  of the hybrid peptlde 
718  Tolerance  Inductton by HIV Fusogemc Pepttde Th-B pepudes, TlSP10IIIB(A) and T1-SP10MN(A) (Table 1), and 
Candida albicans antigen (Greet Laboratories,  Inc., Lenoir,  NC). PHA 
(Burroughs WeUcome, Research Triangle Park, NC) was used m 
a wide dose range as a mltogen m 3-d PBMC [3H]thymldme m- 
corporatmn assays (1, 13). The change m counts per minute was 
calculated as: Acpm  =  experimental cpm  -  control cpm. 
Immuntzation Schedule.  Because  of  our previous studies demon- 
stratmg the lmmunogenicaty ofTh-B peptides in goats and rhesus 
monkeys (13), the initial comparison of pepude designs when this 
study began in 1989 was monthly injectmns of Th-B vs. F-Th-B 
peptides (Table 1) at a dose of"~0 1 mg/kg (6 mgAmmal)  When 
neither pepude design reduced neutrahzing anta-HIVIIIB  anuboches, 
the pepude doses were increased to t0 5 mg/kg (30 mg/animal) 
and the right-hand  side neutralizing sequence of HIVIIIB gp120 
V3 loop (the A regnon) (2, 6) (Table 1) was added to the Th-B 
peptide to enhance the abzhty  of  this peptide to mduce anti-HIVIIIB- 
neutralizing  antibodies  After three monthly injections with ei- 
ther ,,o0 5 mg/kg (30 mg) Th-B or F-Th-B peptide, the animals 
were rested for 6 mo, and then rdmmumzed with either F-Th-B 
or Th-B with sequences from HIVIIIB, or with the Th-B peptide 
containing HIV env gp120 V3 sequences  from the HIVMN uolate. 
Flow Cytometry.  Chimpanzee  PB mononuclear cells  were stu&ed 
by standard flow cytometry methods using a flow cytometer (751, 
Coulter Electronics, Inc., Hialeah, FL). PBL were identified by the 
foUowmg markers; total T cells, CD3; T cell subunits, CD4 and 
CDS,  B cells, CD19; and NK cells, CD56  and CD16. 
Results 
Immunogenicity of Yh-B and F-Th-B Peptides in Chimpanzees 
and Goats for Anti-peptide  and Anti-HIV gp120 Antibody Re- 
sponses.  For chimpanzees immunized with HIVIIIB Th-B 
peptides (chimpanzee nos.  884 and 1028),  antibody to im- 
munizing peptide rose during the initial immunization period 
(Table 2). Chimpanzee no. 1028 developed an abscess at the 
immunization s~te, did not receive the month 5 immuniza- 
tion, and all subsequent immunizations after month 5 in an- 
imal 1028 were in PBS alone. Whereas peak endpoint ELISA 
antipeptide antibody titer at month 4 in animal 1028 was 
1:819,200,  antibody titers fell in animal 1028 after IFA was 
Table 2.  Time Course of Anti-pepade Antibody Responses in Chtmpanzees Immumzed with HIV env Synthetic Th-B or F-Th-B Pepttdes 
Recaprocal of ELISA uter  tkecaprocal of ELISA uter 
Month of 
study  Immunogen dose  No  884  No  1028  Immunogen dose  No.  1045  No.  1070 
mg  mg 
1  0  0  0  0 
2  Th-B(IIIB)  6  0  0  F-Th-B(IIIB) 6  0  0 
3  Th-B(IIIB)  6  51,200  102,400  F-Th-B(IIIB) 6  0  0 
4  Th-B(IIIB) 6  25,600  819,200  F-Th-B(IIIB) 6  0  800 
5  Th-B(IIIB) 6  25,600  204,800"  F-Th-B(IIIB) 6  1,600  200 
6  Th-B(IIIB)  30  51,200  102,400  F-Th-B(IIIB) 30  25,600  12,800 
7  Th-B(IIIB) 30  204,800  102,400  F-Th-B(IIIB) 30  25,600  12,800 
8  Th-B(IIIB) 30  51,200  25,600  F-Th-B(IIIB) 30  6,400  12,800 
9  51,200  51,200  3,200  6,400 
10  12,800  25,600  800  800 
11  51,200  25,600  800  1,600 
12  51,200  25,600  1,600  800 
13  25,600  25,600  200  200 
14  Th-B(IIIB)  6  51,200  25,600  F-Th-B(IIIB)  1  200  400 
15  102,400  12,800  800  800 
16  Th-B(MN) 6  25,600  12,800  Th-B(IIIB) 6  100  0 
17  Th-B(MN) 6  12,800  3,200  Th-B(MN) 6  1,600  3,200 
18  25,600  6,400  6,400  25,600 
19  Th-B(MN) 6  25,600  1,600  Th-B(MN) 6  6,400  51,200 
20  51,200  6,400  Th-B(MN) 6  51,200  102,400' 
Tlters are endpomt ELISA tlters (tlters at whtch E/C were ~3.0) against the Th-B pepude, T1-SPl0IIIB 
* Ammal 1028 dtd not receive  the month 5 mjecuon due to a sterile abscess at the rejection  rite All mjecuons m ammal 1028 after month 5 were 
m PBS alone 
* Ammal 1070 dld not receive the month 20 mamumzauon due to the presence of high levels of ann-HIV-neutrahzmg anubo&es 
For ammals 884 and 1028, unmumzauons at months 2-5 were with T1-SP10IIIB, and months 6, 7, 8, and 14 with T1-SPl0IIIB(A) For ammals 
1045 and 1070, immumzanon at month 16 was with T1-SP10IIIB(A) 
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the remainder of the immunization period (Table 2). In chim- 
panzee no. 884, antibody titers rose at month 7 to 1:204,800 
after five immunizations with Th-B peptides. Continued im- 
munization of animal 884 with high doses of Th-B peptide 
(30 rag/dose) resulted in no further increases  in antibody titer 
(Table 2). 
In contrast,  antipeptide antibody levels were much lower 
during months 1-10 of Immunization of animals 1045 and 
1070 with HIVIIIB F-Th-B peptide, with peak antibody levels 
against tmmunizing peptide of 1:25,600 and 1:12,800 at month 
7 for animals 1028 and 1070, respectively (Table 2). After 
a 6-mo rest for all four animals, animals 884 and 1028 were 
lmmtmized at month 14 with 6 mg of Th-B peptlde. In chim- 
panzee no. 884, boosting w~th Th-B peptide in IFA at month 
14 resulted in rise in titer of anfipeptide antibody to 1:102,400, 
while boosting of animal  1028 with peptide in PBS alone 
led to no antibody rise (Table 2). 
In contrast,  animals 1045 and 1070 were immunized at 
month 14 with 1 mg ("o0.016 mg/kg) of F-Th-B to deter- 
mme if the prior doses of F-Th-B peptide were excessive  and 
induced  high  zone  tolerance,  and  if smaller  amounts  of 
F-derivatized peptide would be more immunogenic. Immu- 
nization of both chimpanzee nos. 1045 and 1070 with 1 mg 
of F-Th-B peptide after a 6-too rest resulted in only minimal 
rises m serum titers of antipepude antibody to 1:800 (Table 2) 
To  determine if chimpanzee  nos.  1045 and  1070 were 
tolerant to Th-B peptides, both animals were immunized on 
month 16 with HIVIIIB Th-B peptide, T1-SP10IIIB(A). Both 
animals 1045 and 1070 responded minimally to boosting v0ath 
Th-B peptide with antipeptide antibody responses of 1.1,600 
and 1:3,200, respectively, demonstrating that animals 1045 
and 1070 were hyporesponsive at month 16 to Th-B HIV 
env epitopes (Table 2). 
Immunization of  Animals 1045 and 1070 with HIVMN Th-B 
Peptide Induced High Levels of Antipeptide Antibodies.  Using 
a previously described strategy of breaking B cell tolerance 
by immunization with an immunogen that is different from, 
but structurally  related to, the tolerogen (14), we next lm- 
mumzed animals 1045 and 1070 with the HIVMN Th-B pep- 
tide. The Th-B peptide from HIVMN contained the same 
Th (T1) gp120 sequence as the HIVIIIB Th-B peptide, but 
contained different B cell gp120 V3 B cell epitope sequences 
than those m the HIVIIIB Th-B peptide (Table 1). After two 
immunizations with Th-B of HIVMN, beginning at month 
17, both chimpanzee nos.  1045 and 1070 had prompt rises 
m titer of antibodies to HIVIIIB (Table 2) and to HIVMN 
Th-B peptide (not shown) to antibody levels that were higher 
than had previously been obtained during the prior 18 mo 
of study At month 20, endpoint ELISA titers to the HIVMN 
Th-B peptide were 1:102,400 for animal 1045 and 1:204,800 
for ammal 1070. 
Chimpanzee  B  Cell Antibody  Responses to  Recombinant 
HIVIIIB gpl20 during the 20-too Immunization Course.  End- 
point ELISA antibody tlters against recombinant HIVIIIB 
gp120 were determined for sera from months 4-7 and 16-20 
to correlate peak antipeptide antibody levels with anu-gp120 
HIV env anubody levels. We found that peak anti-gpl20 an- 
tibody levels in chimpanzee nos. 884 and 1028 during months 
4-7 were both  1:25,600, whereas peak titers  to gp120 m 
ammals 1045 and 1070 during the same period were 1:6,400 
and 0,  respectively. As  with  antipepude antibody levels, 
boosting after a 6-too rest with peptide in PBS in chimpanzee 
no.  1028 did not boost anti-gp120 antibodies. 
Boosting with F-Th-B pepttde at month 14 and with HIVIII 
Th-B at month 16 in animals 1070 and 1045 resulted in min- 
imal  rises in anti-gp120  antibody titers  by month 17  (to 
1:12,800). In contrast,  boosting chimpanzee nos.  1045 and 
1070 with HIVMN Th-B peptide at month 17 induced high 
levels of antl-gp120IIIB antibody in both animals (1:102,400 
and 1:51,200, respectively) by month 20 that rose coincident 
with rises in levels of anttpeptide  antibody. 
Induction of Antipeptzde and Ant~-gpl20 PBMC-proliferative 
Responses by HIV env P~ticles.  Whereas HIVIIIB Th-B pep- 
tides  induced  high  levels (>100,000  Acpm/106  cells) of 
PBMC [3H]thymidme incorporation (animals 884 and 1028) 
(Fig.  1, A  and B) during months 1-8,  F-Th-B peptide did 
not induce levels of [3H]thymldine incorporation  >100,000 
Acpm/106 cells during the same period (Fig. 1, C and D). 
Immunizauon of ammals 1045 and 1070 with Th-B peptide 
at month 16 did not induce the presence of circulating PBMC 
capable of proliferating to Th-B peptide in vitro (Fig. 1, C 
and D) 
Interestingly,  Th-B  peptides  at  months  14-18 boosted 
PBMC-proliferative responses in animal 1028, while antipep- 
tide antibody responses in animal 1028 during this ume were 
not boosted  (Fig.  1 B and Table 1). 
Next, [3H]thymidme mcorporauon of chimpanzee PBMC 
to either recombmant gp120IIIB or to natwe gp120IIIB was 
tested. Table 3 shows the peak [3H]thymidine incorporation 
of chimpanzee PBMC to HIVIIIB gp120 for each animal 
during months 1-13, and demonstrates  that neither chim- 
panzee no.  1070 nor 1045 (recewmg F-Th-B peptide)  had 
PBMC-proliferauve responses to gp120 of E/C >2 through- 
out the first 13 mo of study. In contrast,  animals 884 and 
1028 (receiving Th-B  peptides)  did have anu-gp120-pro- 
liferatwe responses dunng the same period (Table 3). 
To determine ff PBMC-proliferatlve responses to mitogenic 
or antigenic stimuli other than HIV immunogens were normal 
in the F-Th-B-lmmumzed chimpanzees over the 20 mo of 
study, we also measured PBMC-proliferafive  responses to PHA 
(Fig. 2) and to Candida (Fig. 3). While peak PHA PBMC- 
proliferative responses were nearly identical in the four chim- 
panzees, Candida PBMC-proliferauve responses varied from 
animal to animal and from month to month. However, in 
animals 1045 and 1070, we found that Candida responses were 
intermittently present dunng the time of immunization with 
F-Th-B peptide  at levels that were similar to levels present 
before the immunizations were begun (Fig. 3,  C  and D). 
Characterization of  PB Lymphocyte Subsets dunng Immuniza- 
tion of Chimpanzees with HIV env Peptides.  To determine ff 
immumzation with either HIV env peptide type had effects 
on the number of carculating chimpanzee T, B, or NK cell 
populations,  the absolute numbers of these cell types were 
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Figure 1.  Time  course  ofPBMC 
[3H]thymidine incorporation  re- 
sponses to HIV Th-B peptide, T1- 
SP10IIIB(A), in chimpanzees im- 
munized with HIV env synthetic 
peptides. Animals 884 (A) and 1028 
(B) received the Th-B peptide, T1- 
SP101IIB, initially (months 1-5), 
then the Th-B peptide, T-SPl01/IB(A) 
(months 6-8). After a boost with 
the Th-B Peptide, T1-SP10IIIB(A), 
at  month  14,  both  animals 884 
and  1028 were immunized with 
the  HIVMN Th-B  peptide, T1- 
SP10MN(A). C and D show the re- 
sponses of animals 1045 (C) and 
1070 (D) to the HIVIIIB F-Th-B 
Peptide (months 1-14), HIVIIIB 
Th-B  peptide (month  16), and 
HIVMN  Th-B  Peptide (months 
17-19). All  immunizations were 
with the indicated peptide in IFA, 
except for all immunizations  for an- 
imal 1028 after month  4,  which 
were with peptides in PBS alone. 
Solid lines show data for  peak 
proliferative responses (Acpm) to a 
wide dose range of HIVIIIB Th-B 
Peptide. Dotted lines indicate peak 
proliferative response (Acpm) to a 
wide dose range of the HIVMN 
Th-B Peptide. 
determined throughout the immunization period (Fig. 4 and 
Table 4). Whereas preimmunization (before) and postimmu- 
nization (during) lymphocyte levels in animals 884 and 1028 
were not significantly different (Table 4),  animal 1045 be- 
came relatively lymphopenic (p <0.001)  during the course 
of immunization with F-Th-B peptide with the lymphocyte 
count of 650/mm 3 at week 12, compared with preimmuni- 
zation  levels of  2,815 and  2,597  lymphocytes/mm  3  in 
months 1 and 2, respectively (Fig. 4 C). Whereas T cell levels 
significantly dropped an average  of 59 and 44% in chimpanzee 
nos. 1045 (p >0.001) and 1070 (p ;>0.02), respectively, during 
the immunization period, T cell levels did not significantly 
change in animals 884 arid 1028 during the same time (p 2>0.1) 
(Table 4). B and NK cell levels dropped significantly in an- 
imal 1045, but did not change in animals 1070, 884, and 1028 
(Table 4). Taken together, these data demonstrated that im- 
munization with the F-derivatized HIV env peptide induced 
decreases in absolute levels of circulating T cells in both animals 
1045 and 1070, and in B and NK cell levels in animal 1045, 
whereas immunization of chimpanzee nos. 884 and 1028 with 
HIV  Th-B  env  peptides  lacking the  F  domain  did  not 
significantly affect circulating lymphocyte levels. 
Table  3.  FH]thymidine Incorporation of PBMC after In  Vitro Stimulation with HIV env gpl20 
Chimpanzee no.  Immunogen  Preimmunization  Postimmunization 
Acpm/10  ~ cells 
884  Th-B peptides  169  39,189  (232) 
1028  Th-B peptides  17,955  129,121  (7) 
1045  F-Th-B peptide  6,348  12,256  (2) 
1070  F-Th-B peptide  11,285  22,719 (2) 
Data represent the peak gp120 responses observed during the immunization period of months 1-13. Data for animals 884, 1028, and 1045 represent 
peak responses using from 2 to 0.5/xg/ml of HIVIIIB(LAI) recombinant gp120. (Transgene Incorporated, Lyon, France). Data for animal 1070 
represent peak responses using from 1 to 0.5 pg/ml of native HIVIIIB(LAI) gp120 (1). 
Numbers in parentheses represent post-/preimmunization. 
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Figure 2.  Time course of PBMC 
PHlthymidme  incorporation  re- 
sponse to PHA in chimpanzees un- 
mumzed w~th HIV env syntheuc 
pepudes.  Irnmumzat~ons and chim- 
panzees are as in Fig  1 
Ability of HIVIIIB F-Th-B and Th-B Peptides to Induce Anti- 
HIVIIIB-neutralizing Antibodies in Goats.  To determine if the 
F-Th-B peptide used m the imtial phase of the chimpanzee 
immunizatmn protocol was immunogemc in another spe- 
cies, 3 mg of either F-Th-B or Th-B pept~de was used to im- 
munize goats three times over 2 mo and then used to boost 
goats after an 8-too rest (Fig.  5).  We found that after the 
fourth immunization, both peptides were capable of inducing 
serum  anti-HIVIIIB-neutralizing antibodies  (Fig.  5),  and 
capable of inducing high levels (~500,000 Acpm/106 cells) 
of PBMC [3H]thymidine incorporation m vitro to Th-B or 
F-Th-B peptides  (data not shown). In addition, serum end- 
A 
884 
"D 
Tt SptOlaO  TI S  PiGmY,(A)  TI SPIOtlIB(A~  TI ~rlol~l(A~  JL~ 
"~  ~  ~162  I  o i-P-~  I  o1,~r  I  1028 
i 
i 
2  4  6  8  10  12  14  16  18  20 
Month 
2  4  6  8  10  12  I-~  16  Ig  20 
Month 
C 
1045 
o 
TI se~oml~^)  D 
FTJt,  PI~Ua(^,  FT~SptO~C~A~  ~TISP30~J~A~  ~'-r  rlsp1~^~ 
,,o..,,.~  J.'~  ~  ~,  II  1070 
u 
g 
y- 
u 
2  4  6  $  IO  12  14  16  18  20 
Month 
TI SPI~H~ A) 
FT~SF;0U~A~  FTISpIO~Zr~A~  F~')SFIDIIBka~  #,~r  TI$p~M~al 
0  2  4  6  $  IO  12  14  16  Ig 
Month 
Figure 3.  Tune course of PBMC 
[3H]thymldme  incorporation  re- 
sponse to CandJda anugen m chan- 
panzees lmmumzed vath HIV env 
syntheuc pepndes  Immumzauons 
and chunpanzees are as m  Fig.  1 
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Figure 4.  Tmae course of abso- 
lute numbers of lymphocytes and 
lymphocytic subsets m chmapanzees 
mamumzed wtth HIV env synthetac 
pepndes  Immumzatlons and cbam- 
panzees are as m Fig  1  Points rep- 
resent  cell  number/mm  3 of PBL 
and  lymphocyte  subsets  The 
elevated cell numbers mammal 1028 
at month 4 comctded with an ab- 
scess at the mjectlon sites 
point ELISA titers of antibodies to immunizing peptide were 
the same in Th-B- and F-Th-B-immunized goats  (data not 
shown). Thus, failure of the F-Th-B peptide to induce high 
levels of antipeptide antibodies and PBMC-proliferative re- 
sponses in chimpanzees was not due to lack of an inherent 
immunogenicity of the HIVIIIB F-Th-B pepude, but rather 
was due to a specafic effect of the F-denvatized peptide in 
chimpanzees. 
HIVMN Th-B env Peptide Induced  AntvHIV-neutralizing  An- 
tibody in Chimpanzees.  During the first 17 mo of the immu- 
nization trial, serum-neutrahzing antibodies against HIVIIIB 
were always undetectable in syncytmm inhibition  assay and 
were <1:45  in reverse transcriptase inhibition  assay. How- 
ever, after ~mmunization of animals 1045 and 1070 at month 
17 with HIVMN Th-B peptide, antl-HIV-neutralizing anti- 
bodies  were seen in syncytium  inhibition  assay (Table 5). 
To determine why antibodies against HIVIIIB Th-B pep- 
tides did not neutralize HIVIIIB in vitro during the first 17 
mo of immunization,  sera from the early peak anti-HIVIIIB 
pepude antibody responses (month 6) were assayed for reac- 
tiwty to the individual epitopes of the Th-B peptides. We 
found that at the ttme of initial h~gh mers of antl-Th-B pep- 
tide responses, most of the antibody reactivity in sera from 
ammals 884  and 1028 was indeed directed to the primary 
Table  4.  Mean Lymphocyte and Lymphocyte Subset Levels m  Chtmpanzees  before and dunng Immumzatwn wtth HIV env Synthetzc Pepndes 
No  884  No  1028  No  1045  No  1070 
Leukocyte 
subset  Before  Dunng  Change  Before  During  Change  Before  During  Change  Before  During  Change 
cells~ram  3 •  SEA1 
Total 
lymphocytes  4,034  •  452  3,046  •  249 
T  cells  2,629  •  384  2,054  •  178 
B cells  356  •  47  365  •  39 
NK cells  345  •  82  317  •  43 
%  cells~ram  3 •  SEM  %  cells~ram  3 •  SEM  %  cells~ram  3 •  SEM  % 
-26  3,164 •  396  3,286  •  660  +4  3,164  •  397  1,426 •  116  -55"  3,943  •  885  2,768  •  296  -30 
-24  2,565 •  276  2,027  •  402  -21  2,460  •  253  1,012 •  82  -59"  3,337 •  762  1,887 •  184  -44" 
+3  411  •  103  458  •  47  + 11  293  •  32  175  •  15  -40t  302  •  53  232  •  22  -23 
-9  257  •  25  434  •  128  +68  112  •  27  61  •  7  -455  478  •  148  306  •  44  -36 
"Before" samples  were stuched  over a 5-mo period before lmmumzatlon  with peptldes,  n  =  5  for lymphocytes, n  =  3  for T,  B,  and NK ceils 
"Dunng" samples were taken from months 2-14 of lmmumzatlon  n  =  11 for lymphocytes, T, B,  and NK cells  Unless noted, p values for percent 
change companng "before" values  with "dunng" values  were not  s~gmficant,  with p  >0 05  using student's t  test 
*p >0 001 
*p >0OO5 
Sp >0 02 
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Figure  5.  HIV  env  hybrid  syntheuc  pepudes  reduced anu-HIV- 
neutrahzmg antlbo&es m goats  Goat 102A was lmmumzed with 3 mg 
of the F-Th-B peptlde, F-TI-SP10IIIB(A),  and goat 104A was lmmumzed 
with the HIVIIIB Th-B pepude, TI-SP10IIIB  Immumzauons were m 
CFA (first dose) and IFA (doses 2-4)  Neutrahzmg uters are ttters at which 
reverse transcnptase production was inh,blted by 390% 
amino actd sequence of the neutralizing V3 loop region defined 
by the peptide (TRKSIRIQRGPGR)  (Table 6). These data 
suggest  that  antibodies  made by chimpanzee nos.  884  and 
1028  at 7 mo after immunization  with the HIVIIIB Th-B 
HIV env peptides did not recognize the appropnate secondary 
V3 loop structure(s)  necessary for neutralizing HIVIIIB, al- 
though the animals did make antibody responses to the cor- 
rect  primary amino  acid  sequences  of the  neutralizing  V3 
B  cell determinant  of HIVIIIB gp120. 
Discussion 
In this  paper we have shown  that  synthesis  of the HIV 
env gp41 F domain NH2-termmal to synthetic pepudes con- 
taining Th and B cell epitopes of HIV gp120 confe;red on 
the resulting peptlde the ability to reduce immune hyporespon- 
siveness in chimpanzees to Th and B epitopes of HIV gp120 
and  to induce  relative T  cell lymphopenia  These observa- 
tions may have clinical relevance m two areas, the pathophys- 
iology of ineffective anti-HIV host immune responses,  and 
the treatment of pathologic ant~-HIV immune responses m 
HIV infection. 
The pathogenesis of ineffective anti-HIV mamune responses 
in HIV-infected humans is thought to be multffactonal, and 
indudes induction of B and T  cell defects m  antigen respon- 
sweness by HIV, infection of CD4 + APC by HIV, and &- 
rect HIV-mduced T cell death (reviewed in reference 15). Data 
in the present study raise the posslbihty that the HIV gp41 
F  region may reduce immune  hyporesponsiveness m  HIV- 
infected  hosts  to certain  domains  of the  HIV envelope. 
Table  5.  Neutrahzatwn of HIV LAI/IIIB and HIVMN m Syncytmm Inhibmon Assay m Chzmpanzees Immumzed wzth T1-SPIO Pept,des 
Month  18  Month  19  Month  20 
Aroma| no  LAI/IIIB  MN  LAI/IIIB  MN  LAI/IIIB  MN 
884  -  -(20)  ....  (24) 
1028  ...... 
1045  -  -(23)  •  (23)  -(23)  -(22)  -(24) 
1070  •  (92)  -(22)  +(100)  +(96)  •  (86)  +  +(350) 
Data represent the presenc.  ~ of" neutrahzauon m syncytmm mhtbmon assay Numbers m parentheses represent the reciprocal tlter m reverse transcnp- 
tase mhlbmon assay  -,  <48% tnh,bltton  of syncyua  +,  349%  and <80% inhibition of synctua  +,  380%  mhtbmon  of syncma, t~ter 1 10 
+ +,  380%  mhtbttton  of syncytta, ttter  1 20 
Table  6.  Reactwity of Ch:rapanzee Serum wzth Truncated Forms of the Th-B Peptide TI-SPIOIIIB 
Peptlde used 
Chimpanzee no  Bleed  date  T1-SP10IIIB  Tl-flu  SP10C  SP10D  SP10E 
884  Month  7  204,800  800  >102,400"  51,200  3,200 
1028  Month  7  102,400  800  102,400  51,200  3,200 
Data represent endpomt ttters >3 0 E/C m ELISA Pepudes used m ELISA were  T1-SP10IIIB, KQIINMWQEVGKAMYACTRPNNNTKKS- 
IRIQR.GPG,  Tl-flu,  KQIINMWQEVGKAMYATYQR.TRALVTG, SP10C, (C)TR-KSIRIQRGPGK(Y),  SP10D, (C)IRIQRGPGR,  SP10E, 
(C)TRPNNNTRKSIK ELISA  was performed as described m Materials and Methods Flu sequence (TYQRTRALVTG) is from influenza nucleoprotem, 
strata A PR./8/34  (29) 
* E/C at 1 102,400  =  6 0 
724  Tolerance  Inductton by HIV Fusogemc Pepude Immunization of chimpanzees with the F-Th-B  peptide 
did not generally immunosuppress the animals, smce PBMC 
PHA and Candida responses remained mtact. However, in 
both animals immunized with F-Th-B  (1045  and  1070),  a 
relative T  cell lymphopenia developed that was temporally 
related to immunization with the derivatized peptide (Fig. 
4 and Table 4). Thus, we cannot rule out the possibility that 
F-derivatized peptides induced a more general immunosup- 
pressed state than specifc antigen hyporesponslveness. How- 
ever, at present, the immune hyporesponsive state induced 
by F-Th-B peptide most closely resembled classic immune toler- 
ance to specific antigen (14). Immune hyporesponsiveness in 
animals 1045 and 1070 to HIV env determinants was tran- 
sient, and was completely reversed by Immunization of animals 
1045 and 1070 with the Th-B peptide of HIVMN. 
Because the observation of F-Th-B peptide-induced hypo- 
responsiveness was made in only two chimpanzees, consider- 
ation should be given to causes of immune tolerance other 
than immunization w~th F-derivatized peptides.  First, all four 
animals were studied three to four times before immuniza- 
tion and, as well, were studied monthly throughout the 20 mo 
of study. The immune hyporesponslveness seen in animals 
Immunized with fusion domain peptides was a consistent 
finding throughout the time of immunization, and was tem- 
porally related to immunization with F-derivatlzed peptides. 
Moreover, PHA and Candida responses were normal through- 
out  the immunization  ume,  whxle hyporesponsiveness in 
animals 1070 and 1045 was limited to Th and B determmants 
on HIV gp120,  suggesting specificity of hyporesponslveness 
in F peptide-immunized animals. Second, animals were ex- 
amined thoroughly each month throughout the study and 
no intercurrent Illnesses occurred in animals 1045 and 1070 
during the time of immune tolerance Induction. Third, all 
four of the chimpanzees in our study had previously been 
used in hepatitis A, B, and C trials at the National Institutes 
of Health and the Centers for Disease Control  All of the 
animals in the present study were in similar hepatms trials, 
and all are chnically healthy now 10-15  yr after the trials. 
Periodic mild elevations m  liver function tests were noted 
in both Th-B- and F-Th-B-injected animals throughout the 
study period, a phenomenon frequently seen m animals given 
general anesthesia. Thus, the careful momtoring of the animals 
in the study, the consistent findings of hyporesponsiveness 
during the first 16 mo of immunization only in animals tm- 
mumzed with F-derivatized peptides, and the prelmmuniza- 
tion control studies all suggest the immune hyporesponsive- 
ness  seen in  animals  1070 and  1045 to  gp120  Th  and  B 
determinants was due to immunization with F-derlvatized 
peptides. However, given the small number of animals studied, 
we can not conclusively rule out other cofactors that might 
have contributed to our observations. 
Data in the present study may also have relevance to the 
treatment of pathologic anti-HIV immune responses in HIV 
infection. One hypothesis to explain immune deficiency in 
AIDS suggests that the attack of pathologic anti-HIV im- 
mune responses of HIV-lnfected cells may lead to numerous 
manifestations of AIDS (reviewed m  reference 15). For ex- 
ample, regions of the HIV env protein with sequence similar- 
ities to MHC class I and II molecules have been described 
(reviewed in reference 16). Recent data suggest that tissue 
damage m the lymphocytic pneumonia syndrome associated 
with HIV (17) and the skin rash associated with acute simian 
,mmunodeficiency  virus infection in rhesus monkeys (18) are 
due to antiretrovaral CD8 + CTL. Finally, immune-mediated 
destruction of thymic, bone marrow, and lymph node microen- 
vlronments has been postulated to play an euologic role in 
end-stage immune dysfunction in AIDS (reviewed in refer- 
ences 15 and 19). Thus, for pathogenic anti-HIV immune 
responses, what would be needed to treat HIV infecuon and 
prevent the development of climcal AIDS would be the in- 
duction of specific tolerance to HIV antigens that are targets 
of pathologac anti-HIV  immune responses.  Whether  the 
strategy of conjugation of the HIV gp41 F domain to HIV 
immunogens other than those studied would result in toler- 
ance induction is not known. 
The F domain of HIV gp41 has sequence homology to 
several viruses that mediate cell fusion (10). The HIV F do- 
main inserts obliquely into lipid membranes, and has been 
postulated to be an amphlpathic hydrophobic helix in the 
context of a lipid bilayer (20). The more hydrophoblc amino 
acids are proposed to be located on one side of the putative 
helix, with the fusion domam inserting in lipid membranes 
as a sided insertional helical structure at a 70 ~ angle to promote 
membrane fusion (20, 21). The observation that F-derivatlzed 
HIV env peptides induced immune hyporesponstveness in 
chimpanzees, but not m goats or mice (2), suggests that the 
HIV F domain has specificity for interaction with primate 
vs. lower specaes immune cells, although at present, the ex- 
planation for F domain tolerance induction in primates re- 
mains unknown  It is plausible that the F portion of gp41 
m pepttde form can be biologically active. HIV gp41 F domain 
peptides can inhibit HIV-induced cell fusion (22),  and can 
lyse liposomes and insert into planar lipid membranes (23). 
Finally,  an interesting observation in this study was the 
lack of requirement for IFA for boostmg PBMC-proliferative 
responses,  while being required for boost of antibody levels 
m animal 1028 (Table 1 and Fig.  1). One explanation for the 
selective induction of proliferative responses by Th-B pep- 
tides in PBS would be the reduction of Thl-like responses 
(Th for CTL) by peptides in PBS and the induction of Th2-1ike 
(Th for antibody production), as well as Thl-like, responses 
by peptides in IFA (24).  In this regard, we have previously 
shown anti-HIV CTL generation by HIV env peptides m 
PBS in mice (M.  K.  Hart and B.  F.  Haynes, unpubhshed 
results). It has been suggested by some investigators that an- 
tivlral T cell responses may be reqmred for protective anti- 
HIV immunity (reviewed in reference 15), while others have 
suggested that anti-HIV-neutrahzing antibody responses are 
sufficient for protection from HIV challenges (25,  26). 
Thus, the immune responses to peptides seen in this study, 
i.e., Induction of T and B cell anti-HIV responses with IFA, 
the selecuve boost of anti-HIV epitope PBMC-prohferative 
responses  with  peptide  with  no  adjuvant,  and  immune 
hyporesponsiveness to HIV env epitopes with HIV gp41 F 
725  Haynes  et al domain-derivatized pepude,  prov,de several  new  ways  to 
modulate anti-HIV immune responses. Moreover, if ~t is shown 
that conjugation of the HIV F domain to non-HIV peptides 
is also tolerogenic, then the F denvatization of peptide epi- 
topes of antigens that reduce autotmmune or allergic immune 
responses may have potenual for the treatment of human non- 
HIV-related diseases. 
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Note added m proof It has recently been reported that a 23-aa peptlde from the NH2 terminus of gp41 
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